This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): SPP635
Description: SPP635 is a second generation renin inhibitor. Renin is an enzyme in the kidney that stimulates a cascade of biochemical events that cause blood vessels to constrict. Renin inhibitors block the renin-angotensin system at the very top of the cascade. The blockade of the renin-angiotensin system has been shown to deliver not only antihypertensive efficacy but also end-organ protection for the heart (congestive heart failure) and for the kidney (chronic renal disease).
Potential advantages of SPP635 based on pre-clinical and early clinical studies are improved bioavailability (up to 30%), a 24-hour half-life, increased tissue distribution, reduced progression of kidney dysfunction (rat study).
Deal Structure: In December 2001, Speedel acquired a worldwide exclusive license from Roche covering its entire programme in renin inhibition. This license allows Speedel to use the acquired know-how for lead optimisation of its own compounds designated as the SPP600 series. Speedel holds full development and commercialisation rights for these product candidates under the license agreement with Roche. If Speedel decides to offer rights to any Speedel compound from the series to a third party, Roche has a right of first negotiation with respect to such rights. If Roche has not expressed its interest in acquiring such rights within a defined period of time, or the parties have not reached an agreement on the terms of such rights, Speedel is free to grant such rights to any third party.
In September 2008, Speedel was acquired by Novartis.
Additional information available to subscribers only: